Literature reviews, generated by AI
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
6 free credits, then one-time credit packs from $5.
Psoriasis is a chronic, relapsing inflammatory disease for which permanent reversal or cure has not been demonstrated. Current treatments can produce substantial, sometimes complete, skin clearance and may permit prolonged remission after treatment withdrawal, particularly with targeted biologic therapies affecting the IL-23/Th17 pathway. However, relapse remains common, and clinical clearance does not necessarily eliminate the underlying susceptibility to renewed inflammation. Persistent inflammatory memory involving tissue-resident memory T cells and changes in the skin environment may contribute to recurrence. Emerging strategies targeting pathogenic resident cells, innate immune signaling, and tissue-level mechanisms show experimental promise but remain unproven in humans. The available evidence therefore supports effective disease control, remission, and possible disease modification rather than confirmed permanent eradication.
Question: Psoriasis reversal
Read the full reviewDrug dosing must be individualized because age, developmental maturity, body size, organ function, pharmacokinetics, pharmacodynamics, treatment modality, and therapeutic targets can substantially alter drug exposure and response. These considerations are particularly important in neonates, premature infants, children, patients with renal impairment, and critically ill patients receiving continuous renal replacement therapy (CRRT). Initial dosing is influenced mainly by volume of distribution, whereas maintenance dosing depends primarily on clearance. Renal and hepatic dysfunction, developmental changes, fluid shifts, and extracorporeal therapies can therefore require dose reduction, interval extension, or both. Drug-specific examples illustrate the range of dosing challenges, including weight-based acetaminophen dosing in children, indication- and formulation-dependent quetiapine dosing, schedule-dependent decitabine administration, postmenstrual-age-based netilmicin regimens, once-daily gentamicin, and pharmacokinetically guided colistin methanesulfonate therapy. Therapeutic drug monitoring and pharmacokinetic–pharmacodynamic modeling can improve exposure while limiting toxicity, although several regimens remain uncertain and require adherence to disease-specific protocols.
Question: Drugs doses
Read the full reviewHeart failure (HF) is a clinical syndrome caused by structural or functional cardiac abnormalities that impair ventricular filling or ejection, producing inadequate cardiac output, elevated filling pressures, or both. It may involve reduced systolic function, impaired diastolic relaxation and filling, or combined left-, right-, or biventricular dysfunction. Clinical manifestations commonly include dyspnea, fatigue, reduced exercise tolerance, pulmonary or systemic congestion, and peripheral edema. HF is particularly common in older adults, and its prevalence and healthcare burden have increased with population aging and improved survival after cardiovascular disease. Neurohormonal activation initially supports circulation but, when persistent, promotes vasoconstriction, fluid retention, adverse remodeling, and progressive myocardial dysfunction. Diagnosis combines clinical assessment with investigations that characterize ventricular function, congestion, contributing comorbidities, and etiology. Management is individualized and may include lifestyle and comorbidity management, diuretics, vasodilators, neurohormonal therapies, and selected device or exercise-based interventions. Treatment aims to relieve symptoms and congestion, prevent hospitalization, slow progression, and improve survival.
Question: Heart failure
Read the full reviewRecent evidence portrays chronic neuropathic pain as a biologically heterogeneous condition shaped by inherited susceptibility, immune mechanisms, transcriptional and epigenetic regulation, ion-channel dysfunction, mitochondrial impairment, and cellular stress. A genome-wide association study of peripheral neuropathy found no genome-wide significant variants, although subthreshold associations involving CHRDL1, MCF2L, and a long noncoding RNA were related to pain intensity, supporting a polygenic architecture composed of small-effect variants (PMID: 41359007). Complementary Mendelian-randomization studies implicate mitochondrial gene regulation, lipid metabolism, obesity, type 2 diabetes, and vascular disease, while requiring careful validation because of indirect phenotyping and genetic-proxy limitations (PMID: 40943610; PMID: 42081017; PMID: 42152301). Mechanistic studies further identify calcium dysregulation, mitochondrial fission, translational stress, microRNA-mediated ion-channel regulation, inflammatory endothelial signaling, and autoantibody activity as candidate contributors. Collectively, the evidence supports an interacting and clinically diverse molecular framework rather than a single neuropathic-pain pathway.
Question: Search for all peer-reviewed articles published in the past 12 months on neuropathic chronic pain with a genetic or molecular component.
Read the full reviewDiffuse alveolar hemorrhage (DAH) is a potentially life-threatening syndrome caused by bleeding into the alveolar spaces rather than a single disease. Its mechanisms include pulmonary capillaritis, bland pulmonary hemorrhage, and diffuse alveolar damage or vascular injury. Autoimmune pulmonary capillaritis, particularly associated with ANCA-associated vasculitis, anti–glomerular basement membrane (anti-GBM) disease, and systemic lupus erythematosus, is an important cause, but infection, coagulation disorders, cardiovascular disease, medications, toxins, malignancy, transplantation, and other systemic illnesses must also be considered. Diagnosis requires integration of the clinical presentation, serial hemoglobin measurements, imaging, renal and immunologic assessment, microbiology, and selective bronchoscopy with bronchoalveolar lavage. Management begins with urgent respiratory and hemodynamic support, correction of reversible bleeding risks, and treatment of infection when present. Immune-mediated disease generally requires high-dose corticosteroids with etiology-specific immunosuppression, whereas plasma exchange is most clearly relevant to selected anti-GBM presentations and should not be applied indiscriminately in other causes. The evidence base remains limited, relying substantially on retrospective studies, case series, expert opinion, and extrapolation from trials of underlying diseases rather than DAH-specific randomized studies (PMID: 11148710; PMID: 21606695; PMID: 23678356).
Question: What is the current evidence on diffuse alveolar hemorrhage?
Read the full reviewVentilator-associated pneumonia (VAP) is pneumonia developing after at least 48 hours of invasive mechanical ventilation. It is associated with prolonged ventilation, longer intensive care and hospital stays, increased antimicrobial exposure, healthcare costs, and substantial morbidity. Its incidence and attributable mortality are difficult to estimate because definitions, surveillance methods, patient populations, and competing causes of deterioration vary. VAP usually results from aspiration of colonized secretions in the setting of impaired cough and mucociliary clearance, endotracheal-tube biofilm, microaspiration, and critical-illness-associated immune dysfunction. Diagnosis is probabilistic and requires integration of clinical findings, imaging, respiratory microbiology, and alternative diagnoses. Prevention is centered on avoiding unnecessary intubation, shortening ventilation, minimizing sedation, elevating the head of the bed, providing oral and airway care, managing secretions, and maintaining infection-control practices. When VAP is clinically likely, empiric antibiotics should be prompt but adapted to local resistance patterns, prior patient microbiology, illness severity, and multidrug-resistant organism risk. Therapy should be reassessed at 48–72 hours, narrowed or discontinued when appropriate, and generally limited to seven days in clinically improving adults.
Author: aldo lopez
Email: rockmnlr@gmail.com
Question: Provide a comprehensive, evidence-based review of ventilator-associated pneumonia (VAP) in adult intensive care unit patients, including epidemiology, pathophysiology, risk factors, microbiology, diagnosis, prevention strategies, antimicrobial treatment, duration of therapy, antimicrobial stewardship, and recent guideline recommendations.
Recent research has transformed solitary fibrous tumor (SFT) from a primarily morphology-defined lesion into a molecularly characterized fibroblastic neoplasm. The recurrent NAB2–STAT6 fusion, aberrant STAT6 signaling, and nuclear STAT6 immunohistochemistry now provide central tools for diagnosis across diverse anatomic sites. Prognostic assessment combines clinicopathologic features with emerging molecular information, although late recurrence, metastasis, and marked biologic heterogeneity limit prediction. Complete surgical excision remains the foundation for localized disease, with selective radiotherapy and prolonged surveillance. For advanced SFT, antiangiogenic therapies have shown greater activity than conventional chemotherapy, while cytotoxic, immune-based, and molecularly directed strategies remain under investigation. The field is moving toward fusion-based diagnosis, individualized metastatic-risk prediction, and angiogenesis-directed systemic treatment.
Question: new solitary fibrous tumor research
Read the full reviewSpirometry may provide prognostic information in selected patients with heart failure, particularly through forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and classification of obstructive or restrictive ventilatory patterns. Lower FEV₁ and FVC, airflow obstruction, and restrictive patterns have been associated with adverse outcomes in chronic heart failure, HFpEF, and selected HFrEF populations. However, these associations are heterogeneous and may depend on heart-failure phenotype, pulmonary hypertension, and clinical context. Evidence from stable heart failure suggests prognostic value beyond recognized pulmonary disease, whereas studies of advanced heart failure, LVAD evaluation, and some exercise-physiology cohorts have found limited or absent independent associations with mortality or other outcomes. Reduced FEV₁ may have particular relevance among transplant candidates, although evidence is based on a small, selected population. Overall, spirometry is best regarded as an adjunct to clinical, imaging, hemodynamic, biomarker, and exercise-based assessment rather than as a standalone prognostic tool.
Author: aldo lopez
Email: rockmnlr@gmail.com
Question: Is spirometry useful for risk stratification in patients with heart failure?
The available evidence does not establish forced vital capacity (FVC) as an independent prognostic factor for hospital readmission in patients with heart failure. The directly relevant studies either did not identify FVC as an independent predictor or evaluated other pulmonary measures, populations, or outcomes. In smokers hospitalized for heart failure, computed tomography-defined emphysema, rather than FVC or other spirometric measurements, was independently associated with heart-failure readmission (PMID: 30059544). Among patients undergoing left ventricular assist device implantation, reduced diffusing capacity for carbon monoxide independently predicted cardiac readmission, whereas FVC was not evaluated as the prognostic variable (PMID: 33470633). Small-airway dysfunction, assessed by maximum mid-expiratory flow, was associated with a composite of mortality or heart-failure readmission, particularly in patients with left ventricular ejection fraction below 40%, but FVC itself was not an independent predictor (PMID: 40293436). Overall, the evidence remains insufficient to conclude that FVC independently predicts hospital readmission in heart failure.
Author: aldo lopez
Email: rockmnlr@gmail.com
Question: Is forced vital capacity an independent prognostic factor for hospital readmission in patients with heart failure?
Avascular necrosis (AVN), or osteonecrosis, is ischemic and/or cytotoxic death of bone tissue caused by impaired blood supply. Although multiple bones may be affected, the femoral head is the most common site and may undergo progressive necrosis, subchondral fracture, collapse, secondary osteoarthritis, pain, and functional loss. Major associations include corticosteroid exposure, excessive alcohol use, trauma, hematologic and coagulation disorders, metabolic and systemic disease, transplantation-related therapies, and multifocal osteonecrosis. Clinical presentation may be subtle, and plain radiographs can remain normal during early disease. Magnetic resonance imaging (MRI) is therefore central to early detection and staging. Management is determined by stage, lesion size and location, symptoms, age, and functional demands. Early disease may be approached with risk-factor modification, conservative or medical measures, and selected joint-preserving procedures, particularly core decompression. Cell-based augmentation may offer additional benefit, but evidence remains incomplete. After femoral-head collapse or advanced degenerative change, total hip arthroplasty is generally the most reliable treatment.
Question: Avascular necrosis
Read the full review